KRAS and colorectal cancer: As a result, the use of MEK inhibitors in conjunction with PI3K, AKT, or mammalian target of rapamycin (mTOR) inhibitors has not led to desirable outcomes in the treatment of KRAS-mutated colorectal cancer in clinical settings (Atanasova et al., 2023).